BSX · Boston Scientific Corporation
Healthcare NYQ United States bostonscientific.com ↗
BEARISH STRONG BUY
Val Gro Qua Mom Sta Cap P/S3.32 P/E Fwd P/E12.40 PEG0.57 52W –  RSI Target$72.31 (+57.1%) Beta0.58 Div
Loading chart…
RSI (14)
Pattern Overlays
Loading patterns…
Medical Devices Marlborough, United States 59,000 employees
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 54 Overbought · 100
Signal Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
0Bullish
7Bearish
0Neutral
▼ Bear Flag — Breakdown after -10% pole — bearish continuation
▼ Bear Flag — Breakdown after -12% pole — bearish continuation
▼ Double Top — Two peaks ~$58.34 — bearish reversal confirmed
▼ Bear Flag — Breakdown after -14% pole — bearish continuation
▼ Bear Flag — Breakdown after -15% pole — bearish continuation
▼ Bear Flag — Breakdown after -22% pole — bearish continuation
▼ Bear Flag — Breakdown after -9% pole — bearish continuation

View overlays on the price chart via Chart tab → Pattern Overlays.

EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
STRONG BUY
27
4
BuyHoldSell
Price Target Range
$72.31 +57.1% upside
Low $55 High $106
Consensus Current price
Wall Street Analyst Ratings
FirmRatingChangeActionDate
BTIG Buy ↔ Maintain 2026-07-29
Oppenheimer Outperform ↔ Maintain 2026-07-27
Truist Securities Buy ↔ Maintain 2026-07-16
Mizuho Outperform ↔ Maintain 2026-07-15
RBC Capital Outperform ↔ Maintain 2026-07-13
Needham Buy ↔ Maintain 2026-07-08
Evercore ISI Group Outperform ↔ Maintain 2026-07-06
Stifel Buy ↔ Maintain 2026-06-25
Jefferies Buy ↔ Maintain 2026-06-24
Canaccord Genuity Buy ↔ Maintain 2026-06-01
Wolfe Research Peer Perform Outperform Peer Perform ▼ Downgrade 2026-05-29
Citigroup Buy ↔ Maintain 2026-05-28
Leerink Partners Outperform ↔ Maintain 2026-05-28
Barclays Overweight ↔ Maintain 2026-05-28
Wells Fargo Equal-Weight Overweight Equal-Weight ▼ Downgrade 2026-05-28
Baird Outperform ↔ Maintain 2026-05-19
B of A Securities Buy ↔ Maintain 2026-05-18
Goldman Sachs Buy ↔ Maintain 2026-04-23
Raymond James Outperform Strong Buy Outperform ▼ Downgrade 2026-03-30
UBS Buy ↔ Maintain 2026-03-17
JP Morgan Overweight ↔ Maintain 2026-02-05
TD Cowen Buy ↔ Maintain 2026-02-05
Morgan Stanley Overweight ↔ Maintain 2026-02-05
BTIG 2026-07-29
Buy ↔ Maintain
Oppenheimer 2026-07-27
Outperform ↔ Maintain
Truist Securities 2026-07-16
Buy ↔ Maintain
Mizuho 2026-07-15
Outperform ↔ Maintain
RBC Capital 2026-07-13
Outperform ↔ Maintain
Needham 2026-07-08
Buy ↔ Maintain
Evercore ISI Group 2026-07-06
Outperform ↔ Maintain
Stifel 2026-06-25
Buy ↔ Maintain
Jefferies 2026-06-24
Buy ↔ Maintain
Canaccord Genuity 2026-06-01
Buy ↔ Maintain
Wolfe Research 2026-05-29
Peer Perform (from Outperform) ▼ Downgrade
Citigroup 2026-05-28
Buy ↔ Maintain
Leerink Partners 2026-05-28
Outperform ↔ Maintain
Barclays 2026-05-28
Overweight ↔ Maintain
Wells Fargo 2026-05-28
Equal-Weight (from Overweight) ▼ Downgrade
Baird 2026-05-19
Outperform ↔ Maintain
B of A Securities 2026-05-18
Buy ↔ Maintain
Goldman Sachs 2026-04-23
Buy ↔ Maintain
Raymond James 2026-03-30
Outperform (from Strong Buy) ▼ Downgrade
UBS 2026-03-17
Buy ↔ Maintain
JP Morgan 2026-02-05
Overweight ↔ Maintain
TD Cowen 2026-02-05
Buy ↔ Maintain
Morgan Stanley 2026-02-05
Overweight ↔ Maintain
Profitability
Gross Margin 68.94%TTM
Op. Margin 20.60%TTM
ROE 14.66%TTM
Rev. Growth 11.60%YoY
Free Cash Flow 2.81BTTM
FCF Yield TTM
Balance Sheet
Debt / Equity 42.25MRQ
Current Ratio 1.90MRQ
Cash 1.45BMRQ
Total Debt 11.03BMRQ
Net Debt MRQ
How BSX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap68.43B
Enterprise Value78.28B
Trailing P/E19.26
Forward P/E12.40
PEG Ratio (5yr)0.57
Price/Sales (ttm)3.32
Price/Book (mrq)2.65
EV/Revenue3.80
EV/EBITDA14.23
Share Statistics
Avg Vol (3m)20.37M
Shares Outstanding1.49B
Float1.48B
% Held by Insiders0.23%
% Held by Institutions93.84%
Short Ratio1.42
Short % of Float1.90%
Profitability
Gross Margin68.94%
Operating Margin (ttm)20.60%
Profit Margin17.29%
Return on Assets (ttm)6.07%
Return on Equity (ttm)14.66%
Income Statement
Revenue (ttm)20.61B
Revenue Growth (yoy)11.60%
Gross Profit (ttm)14.21B
EBITDA5.50B
Net Income (ttm)3.56B
Diluted EPS (ttm)2.39
EPS Growth (yoy)100.00%
Balance Sheet
Total Cash (mrq)1.45B
Total Debt (mrq)11.03B
Debt / Equity (mrq)42.25
Current Ratio (mrq)1.90
Book Value / Share17.40
Operating CF (ttm)4.34B
Free Cash Flow (ttm)2.81B
Trading & Dividends
Beta (5Y)0.58
50-Day MA47.14
200-Day MA73.92
Fwd Dividend YieldN/A
Payout Ratio0.00%
Ownership Breakdown
Institutional 93.84% Insider 0.23% Public 5.9%
Short Interest 1.90% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in BSX in their latest SEC 13F filing.

Loading…
Insider Transactions
DateInsiderRoleTransactionSharesValue
2026-07-01 MONSON JONATHAN R Chief Financial Officer 2,087
2026-05-28 MAHONEY MICHAEL F Chief Executive Officer Stock Gift at price 0.00 per share. 386,755
2026-05-20 LUDWIG EDWARD J. Director Purchase at price 56.68 per share. 3,580 $202,914
2026-05-20 HABIGER DAVID C Director Purchase at price 55.92 - 56.95 per share. 4,450 $251,098
2026-05-20 PEGUS CHERYL Director Purchase at price 56.49 per share. 1,770 $99,987
2026-05-07 MEGA JESSICA L M.D. Director Stock Award(Grant) at price 0.00 per share. 3,800
2026-05-07 MORANO SUSAN E. Director Stock Award(Grant) at price 0.00 per share. 5,081
2026-05-07 WEBER CHRISTOPHE PIERRE Director Stock Award(Grant) at price 0.00 per share. 2,907
2026-05-07 LUDWIG EDWARD J. Director Stock Award(Grant) at price 0.00 per share. 3,800
2026-05-07 ZANE ELLEN M Director Stock Award(Grant) at price 0.00 per share. 3,800
2026-05-07 WICHMANN DAVID S Director Stock Award(Grant) at price 0.00 per share. 3,800
2026-05-07 HABIGER DAVID C Director Stock Award(Grant) at price 0.00 per share. 3,800
2026-05-01 BUTCHER ARTHUR C Officer 2,102
2026-05-01 O'CONNOR PADRAIG ANDREW Officer 1,802
2026-03-02 MORANO SUSAN E. Director Stock Award(Grant) at price 0.00 per share. 24
2026-03-02 WEBER CHRISTOPHE PIERRE Director Stock Award(Grant) at price 0.00 per share. 879
2026-02-27 WOODWORTH EMILY Officer 838
2026-02-13 FITZGERALD JOSEPH MICHAEL Officer 11,119
2026-02-13 MAHONEY MICHAEL F Chief Executive Officer 41,621
2026-02-13 BUTCHER ARTHUR C Officer 7,956
2026-02-13 MONSON JONATHAN R Chief Financial Officer 3,814
2026-02-13 BROWN VANCE R General Counsel 4,808
2026-02-13 WOODWORTH EMILY Officer 2,711
2026-02-13 O'SULLIVAN MIRIAM Officer 2,702
2026-02-13 O'CONNOR PADRAIG ANDREW Officer 2,595
MONSON JONATHAN R Chief Financial Officer
2026-07-01 2,087 sh
MAHONEY MICHAEL F Chief Executive Officer
Stock Gift at price 0.00 per share.
2026-05-28 386,755 sh
LUDWIG EDWARD J. Director
Purchase at price 56.68 per share.
2026-05-20 3,580 sh $202,914
HABIGER DAVID C Director
Purchase at price 55.92 - 56.95 per share.
2026-05-20 4,450 sh $251,098
PEGUS CHERYL Director
Purchase at price 56.49 per share.
2026-05-20 1,770 sh $99,987
MEGA JESSICA L M.D. Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 3,800 sh
MORANO SUSAN E. Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 5,081 sh
WEBER CHRISTOPHE PIERRE Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 2,907 sh
LUDWIG EDWARD J. Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 3,800 sh
ZANE ELLEN M Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 3,800 sh
WICHMANN DAVID S Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 3,800 sh
HABIGER DAVID C Director
Stock Award(Grant) at price 0.00 per share.
2026-05-07 3,800 sh
BUTCHER ARTHUR C Officer
2026-05-01 2,102 sh
O'CONNOR PADRAIG ANDREW Officer
2026-05-01 1,802 sh
MORANO SUSAN E. Director
Stock Award(Grant) at price 0.00 per share.
2026-03-02 24 sh
WEBER CHRISTOPHE PIERRE Director
Stock Award(Grant) at price 0.00 per share.
2026-03-02 879 sh
WOODWORTH EMILY Officer
2026-02-27 838 sh
FITZGERALD JOSEPH MICHAEL Officer
2026-02-13 11,119 sh
MAHONEY MICHAEL F Chief Executive Officer
2026-02-13 41,621 sh
BUTCHER ARTHUR C Officer
2026-02-13 7,956 sh
MONSON JONATHAN R Chief Financial Officer
2026-02-13 3,814 sh
BROWN VANCE R General Counsel
2026-02-13 4,808 sh
WOODWORTH EMILY Officer
2026-02-13 2,711 sh
O'SULLIVAN MIRIAM Officer
2026-02-13 2,702 sh
O'CONNOR PADRAIG ANDREW Officer
2026-02-13 2,595 sh